Providence, Rhode Island Nov 8, 2024 (Issuewire.com) - TetraPX, a joint venture between Greenspace Labs Inc. and Hangar 420, is excited to announce the launch of its first product, designed to help patients effectively manage chronic pain, TetraPX. This groundbreaking product, now available in over 90% of licensed Rhode Island dispensaries, is a first-of-its-kind formulation that is designed for chronic pain sufferers.
Leveraging the partnership established earlier this year, TetraPX combines scientifically validated combinations of THC and CBD with a proprietary blend of terpenes. Offered in a convenient tablet format, TetraPX enables patients to quickly and easily measure and tailor their dosages according to their individual needs.
Our goal with TetraPX is to provide patients with an extremely high-quality option for managing chronic pain, said Duncan McLaren, CEO of Greenspace Labs. Were proud to provide a product that is clearly labeled and easy to use.
The tablets are produced using the highest quality ingredients, cultivated, manufactured and tested in state-of-the-art facilities. This commitment to quality ensures that patients receive a product they can trust.
Rhode Island, with its growing network of dispensaries, is the first state to experience the benefits of TetraPX. As the market for medical cannabis continues to expand, and the potential of rescheduling cannabis to a schedule 3 product, TetraPX aims to become a nationwide leader in providing effective and reliable chronic pain management solutions.
Combining our expertise in cannabis product development with Greenspace Labs scientific approach has enabled us to create a product that truly meets the needs of patients, said Octavius Prince, CEO of Hangar 420. We believe TetraPX will make a meaningful difference in peoples lives.
For more information about TetraPX and its product offerings, please visit www.tetrapx.com
About Greenspace Labs
Our mission is to bring safe, effective cannabinoid-based treatments to market. We are dedicated to improving the quality of patients lives by addressing conditions with significant unmet medical needs through rigorous scientific research and evidence-based therapeutic development.
Source :TetraPX.com
This article was originally published by IssueWire. Read the original article here.
15 hour's ago
15 hour's ago